Role of cholinesterase inhibitors in dementia care: NICE's economic analysis has limitations
- PMID: 16974027
- PMCID: PMC1570005
- DOI: 10.1136/bmj.333.7568.603
Role of cholinesterase inhibitors in dementia care: NICE's economic analysis has limitations
Comment on
-
Role of cholinesterase inhibitors in dementia care needs rethinking.BMJ. 2006 Sep 2;333(7566):491-3. doi: 10.1136/bmj.38945.478160.94. BMJ. 2006. PMID: 16946340 Free PMC article. Review.
References
-
- Bosanquet N, Yeates A. Modeling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease. Pharmacoeconomics 2006:24: 623-6. - PubMed
-
- National Institute for Health and Clinical Excellence. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine, and memantine for Alzheimer's disease. Health Technology Assessment. (Reference 2, section 6.10, p 157.) - PubMed
-
- Green C, Picot J, Loveman E, Takeda A, Kirby J, Clegg A. Modeling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease. Pharmacoeconomics 2006:24: 1271-82. - PubMed
-
- National Institute for Health and Clinical Excellence. Donepezil, rivastigmine, galantamine (review) and memantine for the treatment of Alzheimer's. London: NICE, 2005. (Technical report No 2.) (Table 6, p 13.)
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical